Technical Analysis for INCY - Incyte Corporation

Grade Last Price % Change Price Change
grade D 79.1 0.97% 0.76
INCY closed up 0.97 percent on Tuesday, September 17, 2019, on 87 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Flat Down Up
See historical INCY trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.97%
New Downtrend Bearish 3.53%
Inside Day Range Contraction 3.53%
Oversold Stochastic Weakness 3.53%
Lower Bollinger Band Touch Weakness 3.98%
Oversold Stochastic Weakness 3.98%

Older signals for INCY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies, as well as baricitinib, a JAK inhibitor, which is Phase III trial for rheumatoid srthritis, Phase IIb trial for psoriasis, and Phase II trial for diabetic nephropathy. The company's products in pipeline also comprise INCB28060 and INCB24360, which are Phase II clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Chemistry Biopharmaceutical Chemical Compounds Organic Compounds Solid Tumors Inflammation Psoriasis Pancreatic Cancer Diabetic Nephropathy Janus Kinase Inhibitor Myelofibrosis Clinical Trial Products Nitriles Sulfonamides
Is INCY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 89.3
52 Week Low 57.0
Average Volume 1,099,784
200-Day Moving Average 79.2427
50-Day Moving Average 81.1718
20-Day Moving Average 80.367
10-Day Moving Average 78.096
Average True Range 2.615
ADX 27.04
+DI 12.2911
-DI 25.896
Chandelier Exit (Long, 3 ATRs ) 78.47499999999999
Chandelier Exit (Short, 3 ATRs ) 82.845
Upper Bollinger Band 85.9051
Lower Bollinger Band 74.8289
Percent B (%b) 0.39
BandWidth 13.782025
MACD Line -1.2066
MACD Signal Line -1.019
MACD Histogram -0.1876
Fundamentals Value
Market Cap 16.27 Billion
Num Shares 206 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -100.13
Price-to-Sales 18.19
Price-to-Book 23.14
PEG Ratio -1.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 81.80
Resistance 3 (R3) 81.59 80.48 81.35
Resistance 2 (R2) 80.48 79.79 80.59 81.20
Resistance 1 (R1) 79.79 79.37 80.14 80.00 81.05
Pivot Point 78.68 78.68 78.85 78.79 78.68
Support 1 (S1) 77.99 77.99 78.34 78.20 77.15
Support 2 (S2) 76.88 77.57 76.99 77.00
Support 3 (S3) 76.19 76.88 76.85
Support 4 (S4) 76.40